Navigation Links
Schulman Associates IRB offers oncology-focused review board
Date:6/25/2012

CINCINNATI, June 25, 2012 /PRNewswire/ -- The fight against cancer continues to be an ongoing challenge for many patients, their families, healthcare providers and economies worldwide. Although significant progress has been made, many forms of the disease remain a public health issue.

According to PhRMA, American biopharma research companies are testing 981 medicines and vaccines to fight the many types of cancer affecting millions of patients. All of the medicines are either in clinical trials or awaiting review by the Food and Drug Administration (phrma.org).

In response to the recent increases in oncology research conducted in North America, Schulman Associates IRB now offers a weekly Board meeting dedicated to the review of oncology research. The new Board's membership consists of a variety of oncology experts, who were carefully recruited from prestigious, nationally recognized research centers, and specifically selected based on their qualifications. Concentrations include pediatric oncology, radiation oncology, oncology research administration and more. The Schulman Oncology Board will meet weekly beginning July 23 and will be one of the leading oncology Boards in North America.

Oncology Board members will also lend their expertise to Schulman's regular Board meetings, as needed. Additional submission materials are not required to take advantage of the Oncology Board's services. Review turnaround times for the Oncology Board will remain consistent with Schulman's standard, competitive timelines.

"This enhanced Board expertise and dedicated additional Board meeting underscore Schulman's commitment to growth and improvement," said Michael Woods, Schulman's president and CEO. "We are delighted to be able to offer an unsurpassed level of service and expertise to our clients who are working to develop new cancer therapies and diagnostics."

The Oncology Board will review both industry-sponsored research as well as federally funded research. As with Schulman's other Review Boards, the Oncology Board will oversee research conducted at universities, hospital systems, community practices and other research sites.

For more information about the Oncology Board, please contact Stephanie Pyle at spyle@sairb.com.

About Schulman Associates IRB
Schulman Associates Institutional Review Board, Inc. ("Schulman") is an independent IRB that has more than 25 years of experience in reviewing research protocols and consent documents to evaluate compliance with relevant regulations and ethical guidelines. As an independent IRB, Schulman is not part of an institution such as an academic medical center or hospital. Schulman can provide IRB services for single and multi-site studies within the United States, Puerto Rico and Canada.  In June 2011, Schulman was awarded full five-year reaccreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP). The Accreditation by AAHRPP demonstrates its commitment to research ethics and human subject protection.


'/>"/>
SOURCE Schulman Associates Institutional Review Board, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical to Present at Todays Security Research Associates 8th Annual Growth Conference
2. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
3. Sensus Healthcare and Texas Dermatology Associates at Baylor University Medical Center Announce the Formation of the SRT University™ Comprehensive Education Series for Practitioners, Healthcare Professionals, and Patients
4. San Diego Based Neurosurgeon Offers Groundbreaking Treatment to Restore Function for People Suffering from Mobility Inhibiting Paralysis
5. New Jersey Ophthamologist Now Offers Pelleve Wrinkle Reduction Treatment
6. New Medical Device Study Offers Key Marketing Budget and Staffing Metrics to Promote Effective Use of Resources
7. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
10. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
11. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... -- Wound care devices and products are used to ... industry mainly consists of establishments engaged in manufacturing wound ... caused by mechanical, chemical, thermal, and radiogenic trauma; and ... skin related diseases, immunological diseases, and other chronic diseases. ... largest region in the wound care devices market in ...
(Date:3/29/2017)... , March 29, 2017 Global intravenous (IV) iron ... billion by 2021, growing at a CAGR of 5%. ... by a doctor to treat anemia or other iron deficiencies. ... in the body. However, in some cases, oral administrations are ... and intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... N.J. , March 29, 2017  Novartis ... Administration (FDA) has accepted the company,s Biologics License ... CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T ... pediatric and young adult patients with B-cell acute ... submission by Novartis for a CAR-T. The priority ...
Breaking Medicine Technology:
(Date:3/30/2017)... DC (PRWEB) , ... March 30, 2017 , ... ... and organizations submitted a letter to President Trump expressing their support for an ... medical doctors, two Ph.D. scientists and one medical journalist, will hold a press ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... ... 2017 , ... Grass pollen is the main cause of hay fever in the United States, ... grass pollen runs from May to July each year; with the worst time for sufferers ... allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are ...
(Date:3/29/2017)... FL (PRWEB) , ... March 30, 2017 , ... Sublime ... the "Spice of Life" or "Wonder Spice", it has been used for thousands of ... in the East," says Heshelow, author of " Turmeric: How to Use it For ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs ... store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these ... Ingredients in HeartBoost, an over the counter heart healthy drink, can reduce Arterial ...
Breaking Medicine News(10 mins):